Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia

Wien Klin Wochenschr. 2016 Apr;128(7-8):234-7. doi: 10.1007/s00508-015-0863-y. Epub 2015 Sep 24.

Abstract

Background: Primary warm autoimmune hemolytic anemia (WAIHA) is a rare autoimmune disorder frequently responding to corticosteroid first-line treatment and effective second-line treatment options such as splenectomy or anti-CD20 antibody therapy. Disease management is frequently hampered by a lack of evidence.

Methods: We have investigated the probability of sustained treatment-free remission after steroid induction to facilitate clinical decision making regarding timing and necessity of second-line treatments. Response data from 31 patients with primary WAIHA initially treated with steroids were retrospectively analyzed. All patients responded by achieving a hemoglobin of at least 10 mg/dl.

Results: After steroid tapering and final withdrawal, 9 of 30 patients remained in unsustained complete remission (CR). The probability of remaining in CR after steroid treatment only was 38.2 % (2 SD 20.6 %) at 15 months. The median remission duration was 100 + months with a range of 12 + to 163 + months. Of note, none of the remaining patients still on steroids achieved CR beyond 15 + months.

Conclusion: These data indicate that a considerable proportion of patients do not need further treatment and that relapses will not occur after 15 months in CR.

Keywords: Warm autoimmune hemolytic anemia; long term remission; steroids.

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / administration & dosage*
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Hemolytic, Autoimmune / diagnosis
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / epidemiology*
  • Austria / epidemiology
  • Computer Simulation
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical*
  • Prevalence
  • Prognosis
  • Remission Induction / methods*
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Adrenal Cortex Hormones